Marina Liberati

8PUBLICATIONS
63CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 07, 2024
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.

Mattia D'Agostino, Delia Rota-Scalabrini, Angelo Belotti

|Mar 28, 2024
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.

Francesca Romana Mauro, Potito Rosario Scalzulli, Lydia Scarfò

|Mar 27, 2024
Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project.

Monica Civallero, Joseph G Schroers-Martin, Steven Horwitz

|Jul 07, 2023
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study.

Guido Gini, Monica Tani, Alessandra Tucci

|Jan 11, 2022
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.

Francesca Romana Mauro, Francesca Paoloni, Stefano Molica

|Dec 08, 2021
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.

Roberto Mina, Antonietta Pia Falcone, Sara Bringhen

Pageof 2

Frequent Collaborators

3 joint publications

Mario Boccadoro

2 joint publications

Alessandra Larocca

2 joint publications

Francesca Gay

2 joint publications

Renato Zambello